Today’s Stock On Watch: It Seems Depomed Incorporated (NASDAQ:DEPO) Will Go Down. Just Reported More Shorted Shares

December 1, 2016 - By Nellie Frank   ·   0 Comments

Today's Stock On Watch: It Seems Depomed Incorporated (NASDAQ:DEPO) Will Go Down. Just Reported More Shorted Shares

The stock of Depomed Incorporated (NASDAQ:DEPO) registered an increase of 3.67% in short interest. DEPO’s total short interest was 11.40M shares in December as published by FINRA. Its up 3.67% from 10.99 million shares, reported previously. With 999,800 shares average volume, it will take short sellers 11 days to cover their DEPO’s short positions. The short interest to Depomed Incorporated’s float is 22.59%. The stock closed at $19.1 during the last session. It is down 4.77% since April 28, 2016 and is uptrending. It has underperformed by 1.15% the S&P500.

Depomed, Inc. is a specialty pharmaceutical firm focused on pain and other central nervous system conditions. The company has a market cap of $1.14 billion.

Insitutional Activity: The institutional sentiment decreased to 0.91 in Q2 2016. Its down 0.33, from 1.24 in 2016Q1. The ratio dropped, as 31 funds sold all Depomed Inc shares owned while 57 reduced positions. 42 funds bought stakes while 67 increased positions. They now own 61.91 million shares or 2.39% less from 63.42 million shares in 2016Q1.
Teachers Advsr last reported 0.01% of its portfolio in the stock. Dimensional Fund Advsr Limited Partnership last reported 1.65 million shares in the company. Quinn Opportunity Prtn Limited has invested 0.26% of its portfolio in Depomed Inc (NASDAQ:DEPO). Jw Asset Mgmt Ltd Com holds 57,924 shares or 0.9% of its portfolio. Tekla Ltd Limited Liability Company has 200,000 shares for 0.16% of their US portfolio. Rhumbline Advisers last reported 0% of its portfolio in the stock. Mckinley Ltd Delaware has 0.16% invested in the company for 173,509 shares. Perceptive Advsrs Ltd Com, a New York-based fund reported 600,000 shares. Creative Planning accumulated 0.01% or 40,075 shares. Arizona State Retirement accumulated 31,721 shares or 0.01% of the stock. Intrust National Bank & Trust Na last reported 15,967 shares in the company. Metropolitan Life Insurance last reported 0.01% of its portfolio in the stock. Wells Fargo Co Mn holds 0% or 43,697 shares in its portfolio. Blackrock has 89,307 shares for 0% of their US portfolio. Teachers Retirement Systems Of The State Of Kentucky has 0% invested in the company for 15,700 shares.

Insider Transactions: Since August 10, 2016, the stock had 0 buys, and 4 selling transactions for $1.04 million net activity. $549,987 worth of Depomed Inc (NASDAQ:DEPO) was sold by Vargas Thadd M on Wednesday, August 10. Moretti August J sold $107,000 worth of stock.

Depomed Inc (NASDAQ:DEPO) Ratings Coverage

Out of 14 analysts covering Depomed Inc (NASDAQ:DEPO), 7 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 50% are positive. Depomed Inc has been the topic of 28 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, November 11 by Roth Capital. The stock of Depomed Inc (NASDAQ:DEPO) has “Hold” rating given on Tuesday, November 8 by Cantor Fitzgerald. The firm has “Hold” rating by WallachBeth Capital given on Friday, July 24. Roth Capital maintained the shares of DEPO in a report on Tuesday, September 1 with “Buy” rating. On Thursday, March 24 the stock rating was initiated by Northland Capital with “Outperform”. UBS initiated Depomed Inc (NASDAQ:DEPO) on Tuesday, February 9 with “Buy” rating. The stock has “Overweight” rating given by Piper Jaffray on Monday, February 8. The rating was initiated by Leerink Swann with “Outperform” on Thursday, March 10. Mizuho upgraded Depomed Inc (NASDAQ:DEPO) on Monday, May 9 to “Buy” rating. Mizuho downgraded Depomed Inc (NASDAQ:DEPO) on Tuesday, October 4 to “Neutral” rating.

DEPO Company Profile

Depomed, Inc., incorporated on August 7, 1995, is a specialty pharmaceutical firm focused on pain and other central nervous system (CNS) conditions. The Company’s products include The NUCYNTA franchise of pain products, including NUCYNTA ER (tapentadol extended release tablets) and NUCYNTA (tapentadol); Gralise (gabapentin); CAMBIA (diclofenac potassium for oral solution); Lazanda (fentanyl) nasal spray, and Zipsor (diclofenac potassium).

Another recent and important Depomed Inc (NASDAQ:DEPO) news was published by Fool.com which published an article titled: “Why Depomed Inc.’s Shares Are Crashing 18.9% Today” on November 08, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>